Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated to v3.5.0, replacing the previous v3.4.3. No study content or results are impacted.SummaryDifference0.1%

- Check10 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe page shows a new site revision note (Revision: v3.4.2) and removes an older funding-status warning and Revision: v3.4.1; these are maintenance updates rather than changes to the trial details or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check45 days agoChange DetectedAdded a government funding lapse notice informing users that information may not be up to date and linking to cc.nih.gov and opm.gov for status updates. The page now shows Revision: v3.4.1, replacing the previous v3.4.0.SummaryDifference0.5%

- Check52 days agoChange DetectedShow glossary was added and QC-related metadata was updated (Last Update Submitted that Met QC Criteria and Revision: v3.4.0). The previous labels Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.2%

- Check66 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.